Imugene (IMU) has joined forces with Merck & Co for a new clinical trial collaboration and supply agreement for the treatment of gastric cancer.
Imugene and MSD, a trade name of Merck, will evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy.
The company said the phase two clinical trial will be done in combination with MSD’s anti-PD1 therapy, pembrolizumab, or chemotherapy in patients with HER-2 positive gastric cancer.
JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Investment Trust’s multi-asset investing approach aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly. This provides an attractive income investing and capital growth opportunity while seeking to maintain lower levels of portfolio volatility than a traditional equity portfolio.